Local peri-lesional therapy with rhGM-CSF for Kaposi's sarcoma

Boente, P.; Sampaio, Cláudio Hoffmann; Brandão, MiguelA.; Moreira, Edson Duarte; Badaró, Roberto; Jones, T. B.

doi:10.1016/0140-6736(93)93174-y

Cited by 53 publications

(16 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunostimulation with interferons is only promising if Thelper cells range above 200/ll [22]. Successful topical treatment of KS with granulocyte monocyte colony stimulating factor has been reported [2]. In our case, a relapse of KS was observed in spite of combined chemoand immunotherapy, so bone marrow transplantation was the last therapeutic option.…”

Section: Discussionmentioning

confidence: 81%

Herpes virus (KSHV) associated kaposi sarcoma in a 3-year-old child with non-HIV-induced immunodeficiency

Kusenbach

Rübben

Schneider

et al. 1997

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 81%

Herpes virus (KSHV) associated kaposi sarcoma in a 3-year-old child with non-HIV-induced immunodeficiency

Kusenbach

Rübben

Schneider

et al. 1997

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…At the initiation of systemic interferon therapy, rhGM-CSF was applied once to the ulcer sur face in order to obtain local proliferation of 111 um/Karlsmark/Svejgaard/UI Iman/Yssi ng fibroblasts and endothelial cells and thus pro mote healing [1,2], which subsequently took place within I month. This was slower than the 10 days observed with lesions related to Kaposi's sarcoma, where rhGM-CSF was administered circumferentially to the lesion [3]. We avoided this particular form of administration for fear of local bleeding due to damage to haemangiomatous vessels pres ent in close proximity to the ulcer.…”

Section: Discussionmentioning

confidence: 92%

“…Clini cally. rhGM-CSF has been used with success to induce closure of Kaposi's sarcoma lesions [3], promote healing of biopsy wounds in patients with leprosy and promote wound healing with autologous skin grafts, where the grafts have been incubated in media contain ing rhGM-CSF [4], We report that rhGM-CSF applied locally to ulcerated areas could be of benefit in promoting healing, especially in the presence of an associated haemangioma, where optimal ulcer care is difficult to attain.…”

mentioning

confidence: 99%

Ulcerated Haemangioma Successfully Treated with Interferon Alfa-2b and Topical Granulocyte-Macrophage Colony-Stimulating Factor

Illum¹,

Karlsmark

Svejgaard

et al. 1995

Dermatology

View full text Add to dashboard Cite

Objective: We tested whether healing and regression could be promoted by granulocyte-macrophage colony-stimulating factor and interferon in a 6-monfh-old girl with an ulcerated haemangioma resistant to systemic steroid therapy. Methods: Interferon alfa-2b (Introna, Schering-Plough) was given subcutaneously once daily at a dose of 3 million units/m² for 5.5 months and rhGM-CSF (Molgramostim, Leucomax; Sandoz/Schering-Plough) 3.33 units was applied on the wound surfaces once and concomitantly with the initiation of interferon therapy. Results: The ulcer healed completely within 1 month and the haemangioma almost totally regressed within 6 months. Conclusion: Local application of rhGM-CSF appears to be effective in promoting ulcer healing in an ulcerated haemangioma otherwise responding to interferon treatment.

show abstract

“…This factor has a potential tissue healing effect, as shown by some reports of its use in skin lessions of leprosy, Kaposi's sarcoma, 39 skin grafts, 40 drug-induced mucositis, 14 chronic leg ulcers, 41 healing cut, burn-wounds, 42 and pressure ulcers. 43 To our knowledge, this is the first report on the use of rhGM-CSF for the treatment of HC.…”

Section: Discussionmentioning

confidence: 99%

Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant

Vela‐Ojeda

Tripp-Villanueva

Sánchez-Cortés

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:In the present study, we assessed the clinical effect of recombinant human granulocyte-macrophage colonystimulating factor (rhGM-CSF) in the treatment of refractory, grade III-IV hemorrhagic cystitis (HC) in six patients who underwent bone marrow transplantation (BMT). These were four males and two females, aged 24-40 years (median age 30.5 years). All received allogeneic BMT from HLA-identical siblings after preparation with busulfan-cyclophosphamide. HC was evident 24.5 days (range 15-33 days) after BMT. Median duration of HC before treatment was 5 days (range 4-9 days). Treatment consisted of intravesical instillation of rhGM-CSF (400 g) for 3 consecutive days. A complete response was observed in three patients, the other three showed a partial response. Median time to achieve response was 36 h (range 0.2-72 h). Hematuria was controlled after the first (two patients), second (two patients) or third (two patients) dose of intravesical rhGM-CSF. Patients were discharged from the hospital 10.5 days (range 3-41 days) after treatment. All patients have been followed for up to 10 months and none have required further treatment. No systemic or bladder side-effects have been observed. Although our results indicate that intravesical instillation of rhGM-CSF is effective in the treatment of HC, a phase II clinical trial, including a larger series of patients, is needed. Keywords: GM-CSF; hemorrhagic cystitis; BMT Hemorrhagic cystitis (HC) is a well-recognized and potentially fatal complication commonly observed in patients who receive high-dose cyclophosphamide (Cy). The incidence in BMT patients is 10-20%. 1-3 Acrolein, a metabolite of Cy, has been implicated as a causative agent. 4 HC after high-dose Cy is prevented by bladder irrigation, hyperhydration 5 and sulfhydryl-containing compounds such as 2-mercapto-ethane (mesna), 6 that inactivate acrolein in the urine. Other known causes of HC include exposure to busulfan, radiation, GVHD and viruses including adenovirus, 7 polyomavirus 8 and cytomegalovirus.HC can be treated by performing hyperhydration, intraCorrespondence: Dr J Vela-Ojeda, Apartado postal 14-878, código postal 07001, México, DF México

show abstract

Local peri-lesional therapy with rhGM-CSF for Kaposi's sarcoma

Cited by 53 publications

References 2 publications

Herpes virus (KSHV) associated kaposi sarcoma in a 3-year-old child with non-HIV-induced immunodeficiency

Herpes virus (KSHV) associated kaposi sarcoma in a 3-year-old child with non-HIV-induced immunodeficiency

Ulcerated Haemangioma Successfully Treated with Interferon Alfa-2b and Topical Granulocyte-Macrophage Colony-Stimulating Factor

Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant

Contact Info

Product

Resources

About